Audited Supplier
Frazer-Baricitinib
Yes
Customized
GMP, HSE, ISO 9001, USP, BP
Elderly, Children, Adult
White Powder
>99%
White Powder
1187594-09-7
2 Years
HPLC
Store Cool Dry Place
Natural
Strictly Quality Control
Worldwide
Welcome to Visit Us
7-10days
C16h17n7o2s
Xi'an Frazer Biotech Co., Ltd.
Foil Bag
99%
China
Product Description
99% High Assay Anti-Rheumatism Pharmaceutical Baricitinib 1187594-09-7
Specification of Analysis
| Items | Standards | Results |
| Appearance | White or off-white solid powder | Complies |
| Identification | By IR | Complies |
| By HPLC | Complies | |
| Solubility | Soluble in DMSO, sparingly soluble in THF and Ace tone, slightly soluble in meth anol, and 0.1N HCl, very sightly soluble in ethanol and dichlo romethane, practically insoluble in water | Complies |
| Melting Point | 213.0ºC~215.0ºC | 213.1ºC~214.6ºC |
| Water Content | ≤ 0.50% | 0.08% |
| Heavy Metals | ≤ 20ppm | Complies |
| Residue on Ignition | ≤ 0.20% | 0.08% |
| Relative Substance | Any single impurity: ≤0.10% | 0.07% |
| Total Impurities: ≤1.00% | 0.18% | |
| Assay (on the anhydrous basis) | 98.0%~102.0% | 99.90% |
| Particle Size | D90: ≤60µm | Complies |
| Reference Standard | In-house Standard | |
| Conclusion | The product complied to In-house standard. | |
| Storage | Preserve in tight,light-resistant containers in a cool place | |
Description:
Baricitinib, sold under the brand name Olumiant among others, is a drug for the treatment of rheumatoid arthritis (RA) in adults whose disease was not well controlled using RA medications called tumor necrosis factor (TNF) antagonists. It acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2. The drug is approved for use in the European Union and the United States.
Indications
1. It is used for the treatment of moderate to severe active rheumatoid arthritis (RA) in adults. Patients with intolerance to one or more anti-rheumatic drugs can be treated with this product. This product can be treated as a single agent or combined with a Combined treatment of methotrexate in Chemicalbook therapy. The efficacy of baricitinib in the treatment of psoriasis, diabetic nephropathy, atopic dermatitis, systemic lupus erythematosus and other diseases is currently in phase II clinical stage.
2. Used in the field of scientific research and chemical reagent.
